Konstantinos C Koskinas1, Stephan Windecker2, Giovanni Pedrazzini3, Christian Mueller4, Stéphane Cook5, Christian M Matter6, Olivier Muller7, Jonas Häner1, Baris Gencer8, Carmela Crljenica3, Poorya Amini9, Olga Deckarm1, Juan F Iglesias8, Lorenz Räber1, Dik Heg9, François Mach8. 1. Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. 2. Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. Electronic address: stephan.windecker@insel.ch. 3. Cardiocentro, Lugano, Switzerland. 4. Department of Cardiology, University Hospital Basel, Basel, Switzerland. 5. Department of Cardiology, Fribourg Hospital and University, Fribourg, Switzerland. 6. Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. 7. Service of Cardiology, Lausanne University Hospital, Lausanne, Switzerland. 8. Department of Cardiology, Geneva University Hospital, Geneva, Switzerland. 9. CTU Bern, University of Bern, Bern, Switzerland.
Abstract
BACKGROUND: Although guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are frequently not attained. Evolocumab, a rapidly acting, potent LDL-C-lowering drug, has not been studied in the acute phase of ACS. OBJECTIVES: The purpose of this study was to assess the feasibility, safety, and LDL-C-lowering efficacy of evolocumab initiated during the in-hospital phase of ACS. METHODS: The authors conducted an investigator-initiated, randomized, double-blind, placebo-controlled trial involving 308 patients hospitalized for ACS with elevated LDL-C levels (≥1.8 mmol/l on high-intensity statin for at least 4 weeks; ≥2.3 mmol/l on low- or moderate-intensity statin; or ≥3.2 mmol/l on no stable dose of statin). Patients were randomly assigned 1:1 to receive subcutaneous evolocumab 420 mg or matching placebo, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg. The primary endpoint was percentage change in calculated LDL-C from baseline to 8 weeks. RESULTS: Most patients (78.2%) had not been on previous statin treatment. Mean LDL-C levels decreased from 3.61 to 0.79 mmol/l at week 8 in the evolocumab group, and from 3.42 to 2.06 mmol/l in the placebo group; the difference in mean percentage change from baseline was -40.7% (95% confidence interval: -45.2 to -36.2; p < 0.001). LDL-C levels <1.8 mmol/l were achieved at week 8 by 95.7% of patients in the evolocumab group versus 37.6% in the placebo group. Adverse events and centrally adjudicated cardiovascular events were similar in both groups. CONCLUSIONS: In this first randomized trial assessing a PCSK9 antibody in the very high-risk setting of ACS, evolocumab added to high-intensity statin therapy was well tolerated and resulted in substantial reduction in LDL-C levels, rendering >95% of patients within currently recommended target levels. (EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes [EVOPACS]; NCT03287609).
RCT Entities:
BACKGROUND: Although guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are frequently not attained. Evolocumab, a rapidly acting, potent LDL-C-lowering drug, has not been studied in the acute phase of ACS. OBJECTIVES: The purpose of this study was to assess the feasibility, safety, and LDL-C-lowering efficacy of evolocumab initiated during the in-hospital phase of ACS. METHODS: The authors conducted an investigator-initiated, randomized, double-blind, placebo-controlled trial involving 308 patients hospitalized for ACS with elevated LDL-C levels (≥1.8 mmol/l on high-intensity statin for at least 4 weeks; ≥2.3 mmol/l on low- or moderate-intensity statin; or ≥3.2 mmol/l on no stable dose of statin). Patients were randomly assigned 1:1 to receive subcutaneous evolocumab 420 mg or matching placebo, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg. The primary endpoint was percentage change in calculated LDL-C from baseline to 8 weeks. RESULTS: Most patients (78.2%) had not been on previous statin treatment. Mean LDL-C levels decreased from 3.61 to 0.79 mmol/l at week 8 in the evolocumab group, and from 3.42 to 2.06 mmol/l in the placebo group; the difference in mean percentage change from baseline was -40.7% (95% confidence interval: -45.2 to -36.2; p < 0.001). LDL-C levels <1.8 mmol/l were achieved at week 8 by 95.7% of patients in the evolocumab group versus 37.6% in the placebo group. Adverse events and centrally adjudicated cardiovascular events were similar in both groups. CONCLUSIONS: In this first randomized trial assessing a PCSK9 antibody in the very high-risk setting of ACS, evolocumab added to high-intensity statin therapy was well tolerated and resulted in substantial reduction in LDL-C levels, rendering >95% of patients within currently recommended target levels. (EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes [EVOPACS]; NCT03287609).
Authors: Thorsten M Leucker; Michael J Blaha; Steven R Jones; Michael A Vavuranakis; Marlene S Williams; Hong Lai; Thomas H Schindler; Jacqueline Latina; Steven P Schulman; Gary Gerstenblith Journal: Circulation Date: 2020-07-27 Impact factor: 29.690
Authors: Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska Journal: Arch Med Sci Date: 2021-11-08 Impact factor: 3.318
Authors: Shyam Prabhakaran; David S Liebeskind; George Cotsonis; Azhar Nizam; Edward Feldmann; Rajbeer S Sangha; Iszet Campo-Bustillo; Jose G Romano Journal: J Stroke Cerebrovasc Dis Date: 2021-10-26 Impact factor: 2.136
Authors: Lorenz Räber; Yasushi Ueki; Tatsuhiko Otsuka; Sylvain Losdat; Jonas D Häner; Jacob Lonborg; Gregor Fahrni; Juan F Iglesias; Robert-Jan van Geuns; Anna S Ondracek; Maria D Radu Juul Jensen; Christian Zanchin; Stefan Stortecky; David Spirk; George C M Siontis; Lanja Saleh; Christian M Matter; Joost Daemen; François Mach; Dik Heg; Stephan Windecker; Thomas Engstrøm; Irene M Lang; Konstantinos C Koskinas Journal: JAMA Date: 2022-05-10 Impact factor: 157.335